Small caps higher at lunch but blue chip brother higher
Junior oilers were making ground as small cap indices went higher but were still left in the rear view mirror by FTSE100.
Company
LON:SCLP
Scancell is a clinical stage biotech company developing immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. With deep roots in cancer immunology and translational research, the company aims to translate its innovation and creativity to address the need for fast, potent and accessible therapies that are easy to administer in hard-to-treat cancers.
328 stories · page 4 of 4
Junior oilers were making ground as small cap indices went higher but were still left in the rear view mirror by FTSE100.
Investments and investor services
Avanti Communications was a high flyer on Aim but the junior market had to cede the spotlight to the big guns this morning
Main share price risers and fallers in London at 4.15pm
Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.
Archive
It was a day to take the bus with Proxama and get off the Tandem
A hot area of cancer research at present, immunotherapy uses the body's own internal biological defences to ward off the disease,
Here are some significant movers at around 2.00pm midweek....
Archive
Biotech group Scancell is to present an update on its immunotherapy technologies at the Biotech Capital Conference in London.
We talk to Dr Richard Goodfellow of Scancell whose researchers are developing a medicine that uses the body’s own defences to cure itself.
Archive
Mining featured predominantly in the news again Wendesday.
Among the landmarks were the data from the phase I/II clinical trial of SCIB1 from the ImmunoBody platform, which delivered extraordinary results for patients with hard to treat melanoma.
Investments and investor services
Electronics group sparked up on potential interest from US rival
Investments and investor services
Precious metal explorer Wishbone said it was in talks to buy a "complementary business"
Some of the main share price movers in London at 1.30pm
ImmunTraCkeR will be used to identify the patients who will benefit most from the cutting edge immunotherapy.
Investments and investor services
Forte Energy, Ferrexpo and MX Oil were also in the news on Thursday
David Evans, outgoing chairman, said: "I have thoroughly enjoyed my eight years as chairman of Scancell and I am proud of its many accomplishments."
Motive Television, VolitionRx and Jersey Oil & Gas were also in the news
A paper in Cancer Research, a leading journal for doctors and surgeons specialising in this area of medicine, outlined the company’s innovative approach to generating vaccines that fight the disease.
The guiding principles of SMARTCO Select were forged in the white heat of Sheffield’s steel industry, according to founder Charles Breese.
Archive
A notable riser was Electric Word (LON:ELE), whose shares added 25% as it announced it has agreed to sell its 70% stake in online magazine iGaming Business to Clarion Events for around £13.8mln.
SCIB1 is programmed to seek out and kill microscopic metastatic cells that are carried by the bloodstream to seed around the body.
Archive
Life was sweet in the world of the small cap miners today.
The highly regarded biotech entrepreneur David Evans, who is Scancell’s chairman, said given the strength of the clinical data from SCIB1 and the pipeline of potential products, further investment is warranted and in his words “could add si
Scancell is at the cutting edge of a new arena of cancer medicine called immuno-oncology that, as mentioned earlier, uses the body’s immune system to combat the disease.
Archive
There has been a significant increase in the resources at Yangibana, the rare earths project in Western Australia, Rare Earth Materials (LON:REM) revealed. Total mineral resources have been upped to 71,828 contained tonnes of total rare ear
It is giving no fewer than six presentations on the company's ImmunoBody and Moditope immunotherapy platforms.
Investments and investor services
It was a bad day for companies with the word 'scan' in their name.